A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages 537-547

  Oh, Seung Hyun ^a,b   Kang, Ju Hee ^b   Kyu Woo, Jong ^c   Lee, Ok Hee ^a   Kim, Edward S ^a   Lee, Ho Young ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b National Cancer Center   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

farnesyl transferase inhibitor; head and neck squamous cell carcinoma; insulin like growth factor binding protein 3; insulin like growth factor 1 receptor; invasion; SCH66336

Indexed keywords

GELATINASE A; LONAFARNIB; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR BLOCKING; TONGUE TUMOR;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; FARNESYLTRANSTRANSFERASE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84862787977     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26373     Document Type: Article

References (50)

1. Marur S, Forastiere AA,. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol 2010; 22: 206-11.
2. Day GL, Blot WJ,. Second primary tumors in patients with oral cancer. Cancer 1992; 70: 14-9.
3. Leon X, Hitt R, Constenla M, Rocca A, Stupp R, Kovacs AF, Amellal N, Bessa EH, Bourhis J,. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 418-24.
4. Saba NF, Khuri FR,. Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. Curr Opin Oncol 2009; 21: 232-7.
5. Duffy MJ, McGowan PM, Gallagher WM,. Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-93.
6. Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Gunzler WA, Janicke F, Graeff H,. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 1992; 297: 112-8.
7. Smith HW, Marshall CJ,. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
8. Kessenbrock K, Plaks V, Werb Z,. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
9. Malinowsky K, Bollner C, Hipp S, Berg D, Schmitt M, Becker KF,. UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers. Curr Med Chem 2010; 17: 4370-7.
10. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku T, Takagi R,. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003; 106: 683-9.
11. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY,. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 653-61.
12. Desrosiers RR, Cusson MH, Turcotte S, Beliveau R,. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration. Int J Cancer 2005; 114: 702-12.
13. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY,. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 2008; 14: 1581-9.
14. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY,. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005; 97: 1272-86.
15. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM,. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002; 62: 3530-7.
16. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY,. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006; 5: 2685-95.
17. Sousa SF, Fernandes PA, Ramos MJ,. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008; 15: 1478-92.
18. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998; 58: 4947-56.
19. Feldkamp MM, Lau N, Roncari L, Guha A,. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001; 61: 4425-31.
20. Whitley BR, Beaulieu LM, Carter JC, Church FC,. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007; 104: 470-9.
21. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC,. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001; 61: 1367-74.
22. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB,. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934-7.
23. Xu W, Neckers L,. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007; 13: 1625-9.
24. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY,. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007; 99: 949-61.
25. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J,. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 2002; 38: 2272-8.
26. Morgillo F, Lee HY,. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006; 15: 709-19.
27. Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK,. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 2004; 96: 1536-48.
28. O'Meara SJ, Kinsella BT,. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor. Biochem J 2005; 386: 177-89.
29. Lebowitz PF, Davide JP, Prendergast GC,. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995; 15: 6613-22.
30. Hensen EF, De Herdt MJ, Goeman JJ, Oosting J, Smit VT, Cornelisse CJ, Baatenburg de Jong RJ,. Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: a pathway-based analysis. BMC Cancer 2008; 8: 168.
31. Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R,. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003; 63: 4796-800.
32. Brodt P, Samani A, Navab R,. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 2000; 60: 1101-7.
33. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES,. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009; 32: 274-9.
34. Wu X, Zhao H, Do KA, Johnson MM, Dong Q, Hong WK, Spitz MR,. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 2004; 10: 3988-95.
35. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY,. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 2006; 239: 136-43.
36. Ouban A, Muraca P, Yeatman T, Coppola D,. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803-8.
37. Brady G, O'Regan E, Miller I, Ogungbowale A, Kapas S, Crean SJ,. Serum levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer. Int J Oral Maxillofac Surg 2007; 36: 259-62.
38. Sohda M, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Masuda N, Kuwano H,. The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer. Anticancer Res 2004; 24: 3029-34.
39. Bahr C, Groner B,. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 2004; 14: 287-95.
40. Garcia-Echeverria C,. Medicinal chemistry approaches to target the kinase activity of IGF-1R. IDrugs 2006; 9: 415-9.
41. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS,. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-40.
42. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-7.
43. Ekman S, Frodin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, Alvfors C, Stahl B, Bergstrom S, Bergqvist M,. Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011; 50: 441-7.
44. Schmitz S, Kaminsky-Forrett M, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Guigay J, Machiels JH,. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol 2010; 28: 15s (suppl; abstr 5500).
45. Patel S, Pappo A, Crowley J, Reinke D, Eid J, Ritland S, Chawla S, Staddon A, Maki R, Vassal G, Helman L,. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor in patients with recurrent or refractory sarcomas. J Clin Oncol 2009; 27 15s (suppl; abstr 10503).
46. Zha J, Lackner MR,. Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy. Clin Cancer Res 2010; 16: 2512-7.
47. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY,. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-11.
48. Chakravarti A, Loeffler JS, Dyson NJ,. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase ignaling. Cancer Res 2002; 62: 200-7.
49. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY,. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13: 2795-803.
50. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008; 68: 8322-32.